CPC A61J 1/1468 (2015.05) [A61J 1/00 (2013.01); A61J 1/065 (2013.01); A61K 31/403 (2013.01); A61K 38/17 (2013.01); A61K 38/1816 (2013.01); A61K 38/193 (2013.01); A61K 38/28 (2013.01); A61K 39/3955 (2013.01); C03C 3/087 (2013.01); C03C 3/091 (2013.01); C03C 4/20 (2013.01); C03C 21/002 (2013.01); C07K 16/241 (2013.01); Y02A 50/30 (2018.01); Y10T 428/131 (2015.01)] | 58 Claims |
1. A delamination resistant pharmaceutical container comprising a pharmaceutical composition stored within the container, wherein the pharmaceutical container comprises a glass composition comprising:
SiO2 in a concentration greater than 74 mol. %;
ZrO2 in a concentration less than 1 mol. %;
alkaline earth oxide comprising MgO and CaO, wherein CaO is present in an amount greater than or equal to 0.1 mol. % and less than or equal to 1.0 mol. % relative to the glass composition, and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %))) is less than or equal to 0.5; and
Y mol. % alkali oxide, wherein the alkali oxide comprises Na2O in an amount greater than 8 mol. %,
wherein the glass composition is free of boron and compounds of boron,
wherein the pharmaceutical composition comprises one of rituximab, bevacizumab, ranibizumab, trastuzumab, an antibody, or an antigen binding fragment thereof, that binds CD20, an antibody, or an antigen binding fragment thereof, that binds vascular endothelial growth factor (VEGF), an antibody, or an antigen binding fragment thereof, that binds vascular endothelial growth factor-A, or an antibody, or an antigen binding fragment thereof, that binds HER2.
|